| アブストラクト | The current conflict between Russia and Ukraine increased concerns in the German population of a release of radioactive substances, e.g.radioactive iodine. A high dose of potassium iodide (PI) may prevent accumulation of radioactive iodine in the thyroid gland. Therefore, the German government keeps a sufficient quantity of PI in stock for public supply in case of an emergency. We investigated ambulatory drug dispensing rates of PI and found that the total dispensing of PI (statutory health insurance (SHI), private health insurance (PHI), and overthe-counter (OTC)) increased by 106% from February to March 2022. Changes in PI dispensing were mainly due to an increase in OTC sales, where PI as an antidote showed a sevenfold increase from around 930 packages (February 2022) to 6,500 packages (March 2022), while SHI and PHI dispensing remained relatively low. Furthermore, we investigated whether these changes in dispensing raised the number of suspected adverse drug reactions (ADR). We found no increase of ADR reports related to the use of PI-containing medicinal products between February and September 2022, neither in our national pharmacovigilance nor in the European EudraVigilance database. The data suggest that the mere possibility of a nuclear disaster in Ukraine raised the demand of PI in Germany. Thus, timely and proactive information and reassurance of the public of supply reliability by the Government in a case of a nuclear emergency could be helpful in preventing potential drug shortages and unfounded concern. |
|---|
| 組織名 | German Institute for Drug Use Evaluation (DAPI), Freie Universitat Berlin,;Berlin, Germany; German Institute for Drug Use Evaluation (DAPI), Heidestr. 7,;10557 Berlin, Germany;, Email: s.enners@dapi.de.;Berlin, Germany.;Drug Commission of German Pharmacists (AMK), Freie Universitat Berlin, Berlin,;Germany.;Berlin, Germany; Drug Commission of German Pharmacists (AMK), Freie Universitat;Berlin, Berlin, Germany; Institute of Pharmacy, Freie Universitat Berlin, Berlin,;Germany; German Institute for Drug Use Evaluation (DAPI), Heidestr. 7, 10557;Berlin, Germany;, Email: m.schulz@fu-berlin.de. |
|---|
